stopped treatment during 5 months follow-up. Higher patient's global score and no use of methotrexate were associated with withdrawal. Longer follow-up will offer additional understanding of the potential efficacy and safety consequences of the non-medical switch. Background: A recent randomized controlled study in a single country reported rates of disease worsening over a one-year follow-up period for innovator infliximab (REMICADE ® , IFX) and a comparator in various diseases including AS and RA. After a mean duration of treatment of 6.7 years of innovator IFX, rates for disease worsening post-one year follow-up were 39.5% in AS and 36.7% in RA 1 . Other such data reporting disease worsening rates are rare. Objectives: Using data from a longitudinal database, the objective was to determine the incidence of disease worsening in AS and RA patients on long-term therapy with innovator IFX. PsA patients were not included in this study due to low numbers (n=49). Methods: BioTRAC is an ongoing, prospective registry of inflammatory arthritis patients initiating treatment with infliximab, golimumab or ustekinumab that has been ongoing since 2002 in Canada. We included AS and RA patients who had been on innovator IFX therapy for at least two, four or six years. Disease worsening endpoint was defined as follows: for AS patients; an increase in ASDAS ≥1.1 from baseline and a minimum score of 2.1. For RA patients; an increase in DAS28 ≥1.2 from baseline and a minimum score of 3.2. Results: This analysis included a total of 196 AS and 425 RA patients. Among AS patients, 36.1% were female, 90.8% were bio-naïve at IFX initiation and 50% were on concomitant NSAID(s) at the 2-year index. The mean (SD) ASDAS score was 2.17 (1.05). As for the RA patients, 75% were female, 88.5% were bio-naïve, and 93% were on concomitant DMARD(s) while 35% were on corticosteroids at the 2-year index. The mean (SD) DAS28 ESR and DAS 28 CRP were 3.37 (1.40) and 3.00 (1.24), respectively. As shown in table 1, the incidence of disease worsening in AS and RA patients on stable IFX for 2-6 years was low and varied from 2.7% to 11.5% at the subsequent 12 and 24 months visit.
where the only studies which assessed risk of recurrence of previous cancer in patients with RA. The RR 0, 77 (IC 95% 0, 29-2,03), did not exhibit an increment in the risk of cancer in these patients. Conclusions: -Studies showed no differences in the incidence of previous cancer in patients treated either with synthetic DMARds or with anti TNF. However, we suggest precaution in the use of these therapies, as the real risk in this population is still unknown.
• The final decision of treating or not treating these patients (risk factors, limitations etc.) needs to be performed in accordance with oncologists.
• There is no strong evidence that could identify the real risk of anti TNF therapies in RA patients, with previous cancer. 1 The potential cross-linking of bivalent anti-IDs with bivalent biologics can result in the formation of large immune complexes (ICs), which are subsequently cleared by mechanisms using the multiple Fc domains, thereby resulting in a decrease in the efficacy of the biologic. Since univalent biologics, such as CZP, only have one binding Fab' arm, such large cross-linked anti-ID-mediated ICs are unlikely to form. Therefore, anti-IDs may have a different effect on the elimination and bioavailability of univalent and bivalent biologics in vivo. Objectives: To determine if the valency of a biologic will affect the in vitro size and in vivo elimination from the plasma of ICs formed with an anti-ID following intravenous (IV) administration to BALB/c mice. Methods: An anti-ID antibody to CZP was generated and used for subsequent studies to mimic an ADAb response. Univalent PF CZP was reengineered as a bivalent FL humanized IgG1 antibody (similar to adalimumab) to directly
